ST. PAUL, Minn., Oct. 17, 2017 /PRNewswire/ — Two new studies by pharmacy benefit manager Prime Therapeutics LLC (Prime) show commercially insured members with rheumatoid arthritis (RA) had 3.5 times higher total cost of care than members without RA. But optimizing conventional disease… https://www.prnewswire.com/news-releases/prime-therapeutics-studies-examine-rheumatoid-arthritis-therapies-and-total-cost-300536842.html
Bristol─Myers Squibb Company announced that the European Commission (EC) has approved Orencia alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis (PsA) in adult http://pharmabiz.com/ArticleDetails.aspx?aid=103403&sid=2
Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be used on the NHS for the treatment of severe active forms of the disease which has not responded to intensive therapy with conventional disease-modifying antirheumatic drugs (DMARDs), it has emerged.
read more http://www.pharmafile.com/news/514503/eli-lilly-arthritis-drug-outperforms-humira-and-receives-nice-backing
Pharma firm’s ‘Behind The Smile’ initiative coincides with RA awareness week http://www.pmlive.com/pharma_news/lilly_and_nras_launch_arthritis_awareness_film_campaign_1196283
(Reuters) – U.S. drugmaker AbbVie Inc said on Wednesday its drug to treat moderate-to-severe rheumatoid arthritis met the main goal in a late-stage study.
The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis (RA) in patients who have not responded to prior therapy.
read more http://www.pharmafile.com/news/514154/sanofi-and-regeneron-score-fda-approval-arthritis
(Reuters) – A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron’s experimental drug to treat rheumatoid arthritis.
NewsRheumatoid arthritis is a chronic inflammatory autoimmune disease that affects 1.5 million people in the United States.Contributed Author: NYUTopics: Disease Research http://www.dddmag.com/news/2017/03/new-assay-may-lead-better-rheumatoid-arthritis-treatment
Pfizer’s phase 3B/4 study evaluating its Xeljanz (tofacitinib citrate) drug, a treatment for moderate to severe rheumatoid arthritis (RA), met its primary endpoint in combination with methotrexate (MTX) against AbbVie’s adalimumab (Humira) but didn’t meet the primary endpoint on its own. http://clinicaltrials.pharmaceutical-business-review.com/news/pfizers-rheumatoid-arthritis-drug-shows-treatment-benefit-in-combination-but-not-alone-170217-5742191